Next Article in Journal
Qualification of Food Intake by the Roma Population in the Region of South Bohemia
Previous Article in Journal
Australia’s Ongoing Legacy of Asbestos: Significant Challenges Remain Even after the Complete Banning of Asbestos Almost Fifteen Years Ago
Previous Article in Special Issue
Aedes Mosquitoes and Aedes-Borne Arboviruses in Africa: Current and Future Threats
Article Menu
Issue 2 (February) cover image

Export Article

Open AccessFeature PaperReview
Int. J. Environ. Res. Public Health 2018, 15(2), 385; https://doi.org/10.3390/ijerph15020385

Immune Responses to Dengue and Zika Viruses—Guidance for T Cell Vaccine Development

1
Functional Genetics of Infectious Diseases Unit, Institut Pasteur, 75015 Paris, France
2
CNRS UMR 2000–Génomique Évolutive, Modélisation et Santé, Institut Pasteur, 75015 Paris, France
3
Virology Group, Universidad El Bosque, Bogotá D.C. 110121, Colombia
*
Author to whom correspondence should be addressed.
Received: 31 January 2018 / Revised: 19 February 2018 / Accepted: 19 February 2018 / Published: 23 February 2018
(This article belongs to the Special Issue Global Epidemics of Zika? Implications for Public Health)
Full-Text   |   PDF [582 KB, uploaded 23 February 2018]   |  

Abstract

Despite numerous efforts to identify the molecular and cellular effectors of the adaptive immunity that induce a long-lasting immunity against dengue or Zika virus infection, the specific mechanisms underlying such protective immunity remain largely unknown. One of the major challenges lies in the high level of dengue virus (DENV) seroprevalence in areas where Zika virus (ZIKV) is circulating. In the context of such a pre-existing DENV immunity that can exacerbate ZIKV infection and disease, and given the lack of appropriate treatment for ZIKV infection, there is an urgent need to develop an efficient vaccine against DENV and ZIKV. Notably, whereas several ZIKV vaccine candidates are currently in clinical trials, all these vaccine candidates have been designed to induce neutralizing antibodies as the primary mechanism of immune protection. Given the difficulty to elicit simultaneously high levels of neutralizing antibodies against the different DENV serotypes, and the potential impact of pre-existing subneutralizing antibodies induced upon DENV infection or vaccination on ZIKV infection and disease, additional or alternative strategies to enhance vaccine efficacy, through T cell immunity, are now being considered. In this review, we summarize recent discoveries about cross-reactive B and T cell responses against DENV and ZIKV and propose guidelines for the development of safe and efficient T cell vaccines targeting both viruses. View Full-Text
Keywords: Zika virus; dengue virus; T cell epitopes; vaccination Zika virus; dengue virus; T cell epitopes; vaccination
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Roth, C.; Delgado, F.G.; Simon-Lorière, E.; Sakuntabhai, A. Immune Responses to Dengue and Zika Viruses—Guidance for T Cell Vaccine Development. Int. J. Environ. Res. Public Health 2018, 15, 385.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Int. J. Environ. Res. Public Health EISSN 1660-4601 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top